Published online Feb 7, 2015. doi: 10.3748/wjg.v21.i5.1641
Peer-review started: June 27, 2014
First decision: August 15, 2014
Revised: August 27, 2014
Accepted: September 30, 2014
Article in press: September 30, 2014
Published online: February 7, 2015
Processing time: 227 Days and 23.4 Hours
AIM: To investigate the association between hypoxia-inducible factor-1α (HIF-1α) polymorphisms (-1772C>T and -1790G>A) and the risk of digestive tract cancer.
METHODS: A total of 13 eligible studies were retrieved from PubMed, EMBASE, and the China National Knowledge Infrastructure database. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of the associations.
RESULTS: By pooling the eligible studies, we found that the HIF-1α -1772C>T polymorphism was not associated with the risk of developing digestive tract cancer (dominant comparison, OR: 1.156; 95%CI: 0.839-1.593; Pheterogeneity = 0.007), and no significant association was found in the Asian population or the Caucasian population. However, for the -1790G>A polymorphism, carriers of the variant -1790A allele had a significantly increased risk of digestive tract cancer compared with those with the wildtype -1790G allele (dominant comparison, OR: 3.252; 95%CI: 1.661-6.368; Pheterogeneity < 0.001). Additionally, this increased risk of digestive cancer was only detected in Asians; there was no significant association in Caucasians.
CONCLUSION: This meta-analysis demonstrates that the HIF-1α -1790G>A polymorphism is associated with a significantly increased risk of digestive tract cancer, while the -1772C>T polymorphism is not.
Core tip: The functional polymorphisms of hypoxia-inducible factor-1α (HIF-1α) (-1772C>T and -1790G>A) have been extensively investigated; however, the relationship between HIF-1α polymorphisms and digestive tract cancer has remained unclear. In this work, we found that the HIF-1α -1772C>T polymorphism was not associated with the overall risk of developing digestive tract cancer (dominant comparison, OR: 1.156; 95%CI: 0.839-1.593; Pheterogeneity = 0.007). However, the variant -1790A allele significantly increased the risk of digestive tract cancer (OR: 3.252; 95%CI: 1.661-6.368; Pheterogeneity < 0.001).